Unexpected interaction between CYP3A4 and BI 11634: is BI 11634 interacting with CYP3A4 similar to nifedipine?

Abstract Background: Interactions between cytochrome P450 3A4 (CYP3A4) and its substrates are complex with multiple binding sites within the active site. BI 11634 is a factor Xa inhibitor in drug development and its interaction with CYP3A4 was evaluated. Methods: Reaction phenotyping studies were conducted to determine human isoform(s) of cytochrome P450 responsible for BI 11634 metabolism using recombinant CYPs and specific chemical inhibitors. Metabolite identification and quantitation were performed for incubations of [14C]BI 11634 with human liver microsomes (HLMs) or recombinant CYP3A4 (rCYP3A4) using a high-performance liquid chromatography-mass spectrometry-radiomatic detector. Inhibition of the CYP3A4-mediated metabolism of BI 11634 by quinidine was further evaluated. Results: From the reaction phenotyping studies, it was shown that the metabolism of BI 11634 in HLM was inhibited by ketoconazole and quinidine, well-accepted specific inhibitors of CYP3A4 and CYP2D6, respectively. In contrast, BI 11634 metabolism was exclusively mediated by rCYP3A4. Additional studies confirmed that BI 11634 was metabolized by CYP3A4 to form one major metabolite and this reaction was inhibited by quinidine with a Ki of 7 µM. Conclusions: These data indicated that BI 11634 may interact with CYP3A4 similar to nifedipine. CYP3A4 substrates have been categorized into three subgroups, including a stand-alone subgroup for dihydropyridine calcium channel blockers such as nifedipine and felodipine. In addition, this study emphasizes the importance of using rCYP in conjunction with approaches relying on inhibition when conducting CYP450 reaction phenotyping studies, as one single method may generate misleading results. The specificity of quinidine as a CYP2D6 inhibitor is questionable as it can also significantly inhibit CYP3A4-mediated metabolism of some compounds.

[1]  Shiew-Mei Huang,et al.  Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[2]  L. Wienkers,et al.  Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation , 2010, Drug Metabolism and Disposition.

[3]  J. Halpert,et al.  Structures of cytochrome P450 3A4. , 2005, Trends in biochemical sciences.

[4]  L. Wienkers,et al.  Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.

[5]  P. Watkins,et al.  THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.

[6]  D. Breimer,et al.  Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans , 1991, Clinical pharmacology and therapeutics.

[7]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[8]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[9]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[10]  S. D. Turner,et al.  Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[11]  A. Y. Lu,et al.  Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[12]  J B Houston,et al.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.

[13]  R. Reeves,et al.  Evaluation of the Pharmacokinetic and Pharmacodynamic Interaction Between Quinidine and Nifedipine , 1993, Journal of clinical pharmacology.

[14]  R. Obach,et al.  Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[15]  A. Galetin,et al.  Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[16]  H. Schoemaker,et al.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics , 2004, European Journal of Clinical Pharmacology.

[17]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[18]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[19]  O Pelkonen,et al.  Inhibition and induction of human cytochrome P450 (CYP) enzymes. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[21]  W. Trager,et al.  Theory for the observed isotope effects from enzymatic systems that form multiple products via branched reaction pathways: cytochrome P-450. , 1989, Biochemistry.